|Bid||2.3900 x 1300|
|Ask||2.6600 x 1100|
|Day's range||2.3819 - 2.6500|
|52-week range||1.5400 - 8.8200|
|Beta (5Y monthly)||-0.01|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Poseida Therapeutics, Inc. (PSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Key Insights Significantly high institutional ownership implies Poseida Therapeutics' stock price is sensitive to their...